2025-02-22 - Analysis Report
## Recursion Pharmaceuticals Inc. (RXRX) Stock Review

**0. Key Figures Summary:**

RXRX has significantly underperformed the S&P 500 (VOO) over the given period.  Its recent price action shows a downward trend, and financial statements reveal ongoing profitability challenges.

**1. Performance Comparison vs. S&P 500 (VOO):**

Recursion Pharmaceuticals Inc. (RXRX) is a clinical-stage biopharmaceutical company leveraging AI and machine learning to discover and develop new drugs.

* **RXRX Cumulative Return:** -1.5978%
* **VOO Cumulative Return:** 42.3547%
* **Return Difference:** -43.95%  (A significant underperformance compared to the S&P 500.)
* **Relative Underperformance Rank:** 30.6% (This means its current underperformance is relatively better than 69.4% of the historical periods based on the min/max range of -83.6% to 45.7%.)

**Alpha/Beta Analysis:**

The provided Alpha/Beta data shows inconsistent performance across different periods, with both positive and negative CAGR and varying Beta values (volatility relative to the market).  The negative Alpha generally indicates underperformance against the benchmark.  High Beta (over 1) suggests higher volatility than the market.

| Year       | CAGR    | MDD   | Alpha | Beta | Cap(B) |
|------------|---------|--------|-------|-------|--------|
| 2021-2023  | -23.0%  | 36.7% | -28.0% | 3.9   |       |
| 2022-2024  | 23.0%   | 36.7% | -10.0% | 0.0   | 2.6    |
| 2023-2025  | 33.0%   | 36.7% | -27.0% | 3.6   |       |


**2. Recent Price Movement:**

* **Closing Price:** $9.28
* **Previous Close:** $10.35
* **Price Change:** -10.34% (Significant daily drop)
* **5-Day Moving Average:** $10.33
* **20-Day Moving Average:** $8.26
* **60-Day Moving Average:** $7.41

The price is below all three moving averages, indicating a bearish trend. The significant daily drop warrants further investigation into potential news or market events.

**3. Technical Indicators & Expected Return:**

* **RSI:** 65.50 (Slightly above the 70 overbought threshold, suggesting potential overvaluation.)
* **PPO:** 2.58 (Positive, indicating bullish momentum, but the magnitude is modest.)
* **20-Day Relative Divergence Change:** +9.0 (Short-term upward movement.)
* **Expected Return (2+ years):** -46.5% (This suggests a substantial underperformance compared to the S&P 500 over the long term, considering the current situation. This needs further investigation as it's unusually low.)

The large negative daily price change (-10.34%) suggests a potential market reaction to negative news, impacting the expected return calculation.

**4. Recent Earnings Analysis:**

The company consistently reports negative EPS, indicating ongoing losses. Revenue is also low and hasn't shown significant growth.

| Date       | EPS      | Revenue     |
|------------|----------|-------------|
| 2024-11-06 | -0.34    | $0.03 B     |
| 2024-08-08 | -0.4     | $0.01 B     |
| 2024-05-09 | -0.39    | $0.01 B     |
| 2023-11-09 | -0.43    | $0.01 B     |
| 2024-11-06 | -0.43    | $0.01 B     | *(Duplicate entry?)*


**5. Financial Information:**

Revenue is growing, but profit margins remain erratic, showing both significant improvements and large losses in recent quarters.  ROE is consistently negative, indicating the company is not generating returns on equity.

**Revenue and Profitability:**

| Quarter     | Revenue    | Profit Margin |
|-------------|------------|---------------|
| 2024-09-30 | $0.03B     | 53.69%        |
| 2024-06-30 | $0.01B     | 36.14%        |
| 2024-03-31 | $0.01B     | 17.23%        |
| 2023-12-31 | $0.01B     | 6.99%         |
| 2023-09-30 | $0.01B     | -7.67%        |


**Capital and Profitability:**

| Quarter     | Equity     | ROE          |
|-------------|------------|--------------|
| 2024-09-30 | $0.52B     | -18.27%       |
| 2024-06-30 | $0.58B     | -16.69%       |
| 2024-03-31 | $0.40B     | -22.78%       |
| 2023-12-31 | $0.46B     | -20.07%       |
| 2023-09-30 | $0.44B     | -21.24%       |


**6. Overall Analysis:**

RXRX shows considerable underperformance against the S&P 500, characterized by negative EPS, volatile profitability, and a bearish price trend. While there are periods of positive CAGR and positive momentum indicators, the overall picture suggests significant risk.  The -46.5% expected return needs further examination as it seems unusually low and might reflect the significant recent price drop.  Investors should carefully consider the high risk and the lack of consistent profitability before investing.  Further research into the reasons behind the recent price drop and the company's long-term growth prospects is crucial.
